Statins are the cornerstone of lipid-lowering pharmacotherapy, reducing cardiovascular morbidity and mortality through inhibition of HMG-CoA reductase and consequent lowering of low-density lipoprotein cholesterol. Additional drug classes with complementary mechanisms expand the therapeutic options available for patients who cannot achieve lipid targets with statins alone or who have specific lipid abnormalities.
What Are Statins and Lipid-Lowering Drugs?
Dyslipidemia, characterized by elevated LDL cholesterol, triglycerides, or reduced HDL cholesterol, is a major modifiable risk factor for atherosclerotic cardiovascular disease. Statins are the most extensively studied and widely prescribed lipid-lowering agents, but other drugs including ezetimibe, fibrates, and PCSK9 inhibitors play important roles in specific clinical scenarios. The choice of therapy depends on the lipid profile, cardiovascular risk, and individual patient factors.
Mechanism of Action
Statins such as atorvastatin, rosuvastatin, and simvastatin competitively inhibit HMG-CoA reductase, the rate-limiting enzyme in the mevalonate pathway of cholesterol synthesis. This inhibition reduces hepatic cholesterol production, triggering upregulation of LDL receptors on hepatocytes and increased clearance of circulating LDL cholesterol. Statins also modestly lower triglycerides and slightly increase HDL cholesterol. Beyond lipid lowering, statins exert pleiotropic effects including improved endothelial function, reduced inflammation, and stabilized atherosclerotic plaques.
Ezetimibe inhibits the Niemann-Pick C1-like 1 protein in the small intestine brush border, reducing dietary and biliary cholesterol absorption. It is often used as add-on therapy to statins to achieve additional LDL reduction. Fibrates such as fenofibrate activate peroxisome proliferator-activated receptor alpha, increasing lipoprotein lipase activity and reducing triglyceride levels while raising HDL cholesterol. PCSK9 inhibitors such as evolocumab are monoclonal antibodies that block proprotein convertase subtilisin/kexin type 9, preventing degradation of LDL receptors and dramatically lowering LDL cholesterol.
Therapeutic Uses
Statins are indicated for primary and secondary prevention of cardiovascular events in patients with elevated LDL cholesterol, diabetes, or established atherosclerotic disease. They reduce the risk of myocardial infarction, stroke, and cardiovascular death. Higher intensity statins provide greater LDL reduction and are recommended for high-risk patients. Ezetimibe is added when additional LDL lowering is needed. Fibrates are primarily used for severe hypertriglyceridemia to prevent pancreatitis. PCSK9 inhibitors are reserved for patients with familial hypercholesterolemia or established cardiovascular disease who cannot reach LDL targets with maximally tolerated statin therapy.
Adverse Effects
The most clinically significant adverse effect of statins is myopathy, ranging from myalgia to rare but serious rhabdomyolysis. Risk factors include high statin dose, advanced age, renal impairment, and interacting medications. Hepatotoxicity is rare, and routine monitoring of liver enzymes is no longer recommended by all guidelines. New-onset diabetes is a dose-dependent effect of statins. Fibrates may cause gallstones and myopathy, particularly when combined with statins.
Contraindications
Statins are contraindicated in active liver disease and pregnancy. Caution is required with concomitant use of potent CYP3A4 inhibitors that increase statin exposure. Ezetimibe is generally well tolerated. Fibrates are contraindicated in severe hepatic or renal impairment and gallbladder disease.
Conclusion
Statins remain the foundation of lipid management due to their robust evidence base for cardiovascular risk reduction. Adjunctive agents including ezetimibe, fibrates, and PCSK9 inhibitors provide additional options for patients with refractory dyslipidemia or specific lipid abnormalities, enabling a personalized approach to cardiovascular prevention.
